D3 Bio
Peter Ho is an accomplished professional in the pharmaceutical and academic sectors, currently serving as Director on the Board of Directors and as a Scientific Advisory Board Member at Overland Pharmaceuticals, as well as in similar advisory roles at HiFiBiO Therapeutics, Tavotek Biotherapeutics, and Accent Therapeutics, Inc. Additionally, Peter holds the position of Adjunct Lecturer at The Johns Hopkins University and Adjunct Associate Professor at UNC Eshelman School of Pharmacy, while also advising the Cleveland Clinic and acting as a Senior Advisor at D3 Bio. With a strong educational background that includes an M.D. and Ph.D. from the Yale School of Medicine and a Bachelor of Arts in Biology from The Johns Hopkins University, Peter has demonstrated significant expertise in the fields of medicine and pharmacology.
This person is not in any teams
This person is not in any offices
D3 Bio
1 followers
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated. They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path. D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.” D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.